Views:0 Author:Site Editor Publish Time: 2020-05-30 Origin:Site
The approval of new weight-loss drugs must adhere to the efficacy and safety simultaneously. In terms of curative effect, the listed weight loss drugs meet the FDA's efficacy evaluation criteria for weight loss drugs: (1) Weight loss drugs and placebo after 1 years, 2 groups of participants in the weight loss should be no less than 5%. (2) The proportion of subjects with 5% or more weight loss in the drug treatment group was not less than 35%, and the proportion should be twice times that of the placebo group. But weight-loss drugs in the treatment of good weight loss at the same time, there are serious security problems. One of the most notorious is the appetite inhibitor amphetamine (fenfluramine) and Amphetamine (phentermine), which were widely used in the the 1990s because of appetite inhibition, but were forced out of the market due to pulmonary hypertension and valvular heart disease. Other amphetamine-like and quasi-sympathetic drugs also have serious risks of addiction, myocardial toxicity and sudden death. The mortality of chronic pulmonary hypertension caused by Amire (Aminorex) is 50%. Amphetamine-amine (phenylpro-panolamine) can cause intracranial hemorrhage and stroke. Ephedrine (ephedrine) can cause heart disease, high blood pressure, palpitation, stroke and sudden death. Sibutramine sibutramine (sibutramine) can cause increased cardiovascular disease.
Rimonabant (rimonabant) is an endogenous cannabis receptor CBL antagonist that can lead to increased depression and suicide. These unsafe drugs have been withdrawn from the market. At present, there are still 5 kinds of slimming drugs in clinical use, including 1999 approved Orlistat (ORLISTAT) Capsules, The green Kaslin (Lorcaserin) and amphetamine and topiramate (Qsymia) slow release capsules approved in 2012, and the 2014 approved hydrochloride and ketamine hydrochloride compound sustained release tablets (Contrave) and liraglutide peptide (liraglutide) injection.